Of note, those considerations are further fueled by the fact that a recent trial investigating uptake on FAPI PET/CT in benign diseases also reported on the spine, followed by the shoulders as the most frequent locations of relevant in-vivo FAP upregulation in patients with arthritis or inflammatory-related abnormalities [13]. The gene discussed is FAP; the disease is Arthritis.